title: Efficacy and safety of 0.1% retinaldehyde/ 6% glycolic acid (diacneal) for mild to moderate acne vulgaris. A multicentre, double-blind, randomized, vehicle-controlled trial.
abstract: BACKGROUND
  Retinaldehyde and glycolic acid are both efficient in acne.
  
  
  OBJECTIVE
  To evaluate the efficacy and tolerability of a 0.1% retinaldehyde/6% glycolic acid combination (Diacneal) for mild to moderate acne vulgaris.
  
  
  METHODS
  Overall physician and patient ratings of acne symptom severity and tolerance were performed at baseline, months 1, 2 and 3.
  
  
  RESULTS
  Mean numbers of papules, pustules and comedones were significantly reduced from month 1 onwards. A significant advantage of Diacneal over vehicle was demonstrated on the percentages of patients with ongoing healing lesions at month 2, healing ancient lesions from month 1 and patients with 'important/very important' global improvement from month 2 (50.0 vs. 26.3%) confirmed by patients at month 3 (86.1 vs. 58.8%). Products were well tolerated; only 1 patient had to stop the treatment.
  
  
  CONCLUSIONS
  Diacneal, a combination of 0.1% retinaldehyde/6% glycolic acid, is effective and well tolerated in mild to moderate acne vulgaris.
authors.affiliation: Paris, France. florence.poli@hmn.ap-hop-paris.fr
authors.forename: F
authors.initials: F
authors.lastname: Poli
authors.forename: V
authors.initials: V
authors.lastname: Ribet
authors.forename: C
authors.initials: C
authors.lastname: Lauze
authors.forename: H
authors.initials: H
authors.lastname: Adhoute
authors.forename: P
authors.initials: P
authors.lastname: Morinet
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy* / Q000473:pathology; D000293:Adolescent; D000328:Adult; D001706:Biopsy; D002648:Child; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006016:Glycolates / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007641:Keratolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D017060:Patient Satisfaction; D014677:Pharmaceutical Vehicles; D012074:Remission Induction; D012172:Retinaldehyde / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects
chemical_list: D003879:Dermatologic Agents; D004338:Drug Combinations; D006016:Glycolates; D007641:Keratolytic Agents; D014677:Pharmaceutical Vehicles; C501639:diacneal; C031149:glycolic acid; D012172:Retinaldehyde